According to George Perros, Greystone Research Managing Director, evolution in pain management guidelines and a better appreciation for pain-associated morbidity by clinicians are making pain management more essential for patients. Greystone’s study, “Transdermal Pain Management to 2015,” analyses commercial transdermal prescription drug products and development-stage candidates, as well as examining key factors influencing market demand and shaping growth prospects.
Read the Greystone Research Associates press release on transdermal pain products.
